FOX Translator
No data currently available.
No data currently available.
Just as your pulse is checked during a routine physical, free cash flow is used as an indicator of a company's health. It equals the cash brought in from operations minus the money needed to pay the bills. Think about leftover money in your checking account after you pay this month's bills.
Investors and analysts see this leftover money as a gauge of a company's ability to perform. It is available for transactions such as handing out dividends and working on new products.
Some argue free cash flow is wrongly overshadowed by the emphasis often placed on earnings. Earnings numbers can be manipulated and don't always tell the whole story -- and earnings don't mean much if there's nothing left over after a company pays its expenses. Even if you bring in a six-figure salary, but no money left after paying the bills, are you in great financial shape?
You don't have to be Einstein to figure out free cash flow. To calculate the number, subtract the company's expenditures and dividends from its operating cash flow.
If the free cash flow is written in red ink, it doesn't necessarily signal curtains. This is common for young companies looking to grow. It also could be a result of heavy investments, which in the long run could be worth a standing ovation.
Home / Markets / Industries / Finance
Friday, August 01, 2008
Bioheart, Inc. to Present at Red Chip Investor Conference in New York
Comtex
SUNRISE, Fla., Aug 01, 2008 /PRNewswire-FirstCall via COMTEX/ ----Bioheart, Inc. (Nasdaq: BHRT) today announced that Howard J. Leonhardt, Chairman and CEO of Bioheart, will present a corporate overview Thursday, August 21, 2008 at 9:30 a.m. ET during the Red Chip Investor Conference at the Marriott Marquis in New York. A live audio webcast and slide presentation will be available via the internet by visiting and registering to attend at: http://www.redchip.com.
ABOUT BIOHEART, INC.
Bioheart, Inc., (Nasdaq: BHRT) is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. For more information on Bioheart, visit http://www.bioheartinc.com.
MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc. Contact: William Kline Lytham Partners, LLC Chief Financial Officer Joe Diaz Nicholas Burke Joe Dorame VP - Financial Operations Robert Blum (954) 835-1500 (602) 889-9700
SOURCE Bioheart, Inc.
http://www.bioheartinc.com
Copyright (C) 2008 PR Newswire. All rights reserved
Market Snapshot
| Symbol | Last Price | Netchange | Volume |
|---|---|---|---|
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
